Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 117

1.

The Transient Receptor Potential Vanilloid 1 Is Associated with Active Inflammation in Ulcerative Colitis.

Toledo-Mauriño JJ, Furuzawa-Carballeda J, Villeda-Ramírez MA, Fonseca-Camarillo G, Meza-Guillen D, Barreto-Zúñiga R, Yamamoto-Furusho JK.

Mediators Inflamm. 2018 Jul 29;2018:6570371. doi: 10.1155/2018/6570371. eCollection 2018.

2.

Caspase recruitment domain (CARD) family (CARD9, CARD10, CARD11, CARD14 and CARD15) are increased during active inflammation in patients with inflammatory bowel disease.

Yamamoto-Furusho JK, Fonseca-Camarillo G, Furuzawa-Carballeda J, Sarmiento-Aguilar A, Barreto-Zuñiga R, Martínez-Benitez B, Lara-Velazquez MA.

J Inflamm (Lond). 2018 Jul 11;15:13. doi: 10.1186/s12950-018-0189-4. eCollection 2018.

3.

Hospital Anxiety and Depression Scale (HADS): Validation in Mexican Patients with Inflammatory Bowel Disease.

Yamamoto-Furusho JK, Sarmiento-Aguilar A, García-Alanis M, Gómez-García LE, Toledo-Mauriño J, Olivares-Guzmán L, Fresán-Orellana A.

Gastroenterol Hepatol. 2018 Jun 21. pii: S0210-5705(18)30138-9. doi: 10.1016/j.gastrohep.2018.05.009. [Epub ahead of print] English, Spanish.

PMID:
29937084
4.

Inflammatory bowel disease therapy: blockade of cytokines and cytokine signaling pathways.

Yamamoto-Furusho JK.

Curr Opin Gastroenterol. 2018 Jul;34(4):187-193. doi: 10.1097/MOG.0000000000000444.

PMID:
29846261
5.

Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico.

Mayoral-Zavala A, Esquivel-Aguilar A, Del Real-Calzada CM, Gutiérrez-Grobe Y, Ramos-García J, Rocha-Ramírez JL, Rojas-Illanes MF, Rubio-Martínez B, Sánchez-Chávez X, Yamamoto-Furusho JK; Grupo Académico y de Investigación en Crohn y Colitis Ulcerosa Idiopática de México (GAICCUM).

Rev Gastroenterol Mex. 2018 Apr 20. pii: S0375-0906(18)30083-1. doi: 10.1016/j.rgmx.2018.03.003. [Epub ahead of print] English, Spanish.

6.

Evaluation of a vaccination regimen and care in relation to follow-up and treatment of patients with inflammatory bowel disease.

Yamamoto-Furusho JK, Sarmiento-Aguilar A, Parra-Holguín NN, Bozada-Gutiérrez KE.

Rev Gastroenterol Mex. 2018 Mar 28. pii: S0375-0906(18)30053-3. doi: 10.1016/j.rgmx.2018.02.003. [Epub ahead of print] English, Spanish.

7.

The Mexican consensus on the diagnosis and treatment of ulcerative colitis.

Yamamoto-Furusho JK, Gutiérrez-Grobe Y, López-Gómez JG, Bosques-Padilla F, Rocha-Ramírez JL; Grupo del Consenso Mexicano de Colitis Ulcerosa Crónica Idiopática.

Rev Gastroenterol Mex. 2018 Apr - Jun;83(2):144-167. doi: 10.1016/j.rgmx.2017.08.006. Epub 2018 Mar 2. English, Spanish.

8.

Joint involvement in Mexican patients with ulcerative colitis: a hospital-based retrospective study.

Yamamoto-Furusho JK, Sarmiento-Aguilar A.

Clin Rheumatol. 2018 Mar;37(3):677-682. doi: 10.1007/s10067-017-3834-z. Epub 2017 Sep 15.

PMID:
28914369
9.

Pharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategies.

Yamamoto-Furusho JK.

Pharmgenomics Pers Med. 2017 May 26;10:197-204. doi: 10.2147/PGPM.S109648. eCollection 2017. Review.

10.

Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part).

Yamamoto-Furusho JK, Bosques-Padilla F, Daffra P, De Paula JA, Etchevers J, Galiano MT, Ibañez P, Juliao F, Kotze PG, Marroquín de la Garza JM, Monreal Robles R, Rocha JL, Steinwurz F, Vázquez-Frías R, Veitia G, Zaltman C.

Rev Gastroenterol Mex. 2017 Apr - Jun;82(2):134-155. doi: 10.1016/j.rgmx.2016.07.005. Epub 2017 Mar 16. English, Spanish.

11.

Effect of Cis-palmitoleic acid supplementation on inflammation and expression of HNF4γ, HNF4α and IL6 in patients with ulcerative colitis.

Bueno-Hernández N, Sixtos-Alonso MS, Milke García MDP, Yamamoto-Furusho JK.

Minerva Gastroenterol Dietol. 2017 Sep;63(3):257-263. doi: 10.23736/S1121-421X.17.02367-4. Epub 2017 Feb 9.

PMID:
28185444
12.

The Mexican consensus on probiotics in gastroenterology.

Valdovinos MA, Montijo E, Abreu AT, Heller S, González-Garay A, Bacarreza D, Bielsa-Fernández M, Bojórquez-Ramos MC, Bosques-Padilla F, Burguete-García AI, Carmona-Sánchez R, Consuelo-Sánchez A, Coss-Adame E, Chávez-Barrera JA, de Ariño M, Flores-Calderón J, Gómez-Escudero O, González-Huezo MS, Icaza-Chávez ME, Larrosa-Haro A, Morales-Arámbula M, Murata C, Ramírez-Mayans JA, Remes-Troche JM, Rizo-Robles T, Peláez-Luna M, Toro-Monjaraz EM, Torre A, Urquidi-Rivera ME, Vázquez R, Yamamoto-Furusho JK, Guarner F.

Rev Gastroenterol Mex. 2017 Apr - Jun;82(2):156-178. doi: 10.1016/j.rgmx.2016.08.004. Epub 2017 Jan 16. English, Spanish.

13.

Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation.

Yamamoto-Furusho JK, Bosques-Padilla F, de-Paula J, Galiano MT, Ibañez P, Juliao F, Kotze PG, Rocha JL, Steinwurz F, Veitia G, Zaltman C.

Rev Gastroenterol Mex. 2017 Jan - Mar;82(1):46-84. doi: 10.1016/j.rgmx.2016.07.003. Epub 2016 Dec 13. English, Spanish.

14.

Interleukin 27 is up-regulated in patients with active inflammatory bowel disease.

Furuzawa Carballeda J, Fonseca Camarillo G, Yamamoto-Furusho JK.

Immunol Res. 2016 Aug;64(4):901-7. doi: 10.1007/s12026-016-8804-z.

PMID:
27221243
15.

Genetic polymorphisms of interleukin-22 in patients with ulcerative colitis.

Yamamoto-Furusho JK, Sánchez-Morales GE, García-Rangel D, Vargas-Alarcón G.

Rev Gastroenterol Mex. 2016 Apr-Jun;81(2):86-90. doi: 10.1016/j.rgmx.2016.02.002. Epub 2016 Mar 16. English, Spanish.

16.

Protective role of Interleukin 27 (IL-27) gene polymorphisms in patients with ulcerative colitis.

Yamamoto-Furusho JK, Posadas-Sánchez R, Alvarez-León E, Vargas-Alarcón G.

Immunol Lett. 2016 Apr;172:79-83. doi: 10.1016/j.imlet.2016.02.010. Epub 2016 Feb 18.

PMID:
26905929
17.

Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis.

Yamamoto-Furusho JK, Ascaño-Gutiérrez I, Furuzawa-Carballeda J, Fonseca-Camarillo G.

Mediators Inflamm. 2015;2015:659018. doi: 10.1155/2015/659018. Epub 2015 Dec 6.

19.

Genetic Markers Associated with Clinical Outcomes in Patients with Inflammatory Bowel Disease.

Yamamoto-Furusho JK, Fonseca-Camarillo G.

Inflamm Bowel Dis. 2015 Nov;21(11):2683-95. doi: 10.1097/MIB.0000000000000500. Review.

PMID:
26244649
20.

Interleukin 35 (IL-35) and IL-37: Intestinal and peripheral expression by T and B regulatory cells in patients with Inflammatory Bowel Disease.

Fonseca-Camarillo G, Furuzawa-Carballeda J, Yamamoto-Furusho JK.

Cytokine. 2015 Oct;75(2):389-402. doi: 10.1016/j.cyto.2015.04.009. Epub 2015 Jun 30.

PMID:
26141420

Supplemental Content

Loading ...
Support Center